CA Patent

CA2694983A1 — Treatments of b-cell proliferative disorders

Assigned to Zalicus Inc · Expires 2009-01-22 · 17y expired

What this patent protects

The invention provides compositions and methods for the treatment of B-cell proliferative disorders that employ an A2A receptor agonist or one or more PDE inhibitors. The methods and compositions may further include an antiproliferative compound.

USPTO Abstract

The invention provides compositions and methods for the treatment of B-cell proliferative disorders that employ an A2A receptor agonist or one or more PDE inhibitors. The methods and compositions may further include an antiproliferative compound.

Drugs covered by this patent

Patent Metadata

Patent number
CA2694983A1
Jurisdiction
CA
Classification
—
Expires
2009-01-22
Drug substance claim
No
Drug product claim
No
Assignee
Zalicus Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.